Sucampo/Takeda’s Amitiza First To Fill Zelnorm Void In IBS Market

With the addition of an irritable bowel syndrome indication, Sucampo Pharmaceuticals has expanded the market opportunity for its chronic idiopathic constipation drug Amitiza by about 20 million patients

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet